Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 25.65 USD 2.07% Market Closed
Market Cap: 145.4B USD
Have any thoughts about
Pfizer Inc?
Write Note

Pfizer Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pfizer Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Pfizer Inc
NYSE:PFE
Additional Paid In Capital
$93.2B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
2%
Johnson & Johnson
NYSE:JNJ
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Additional Paid In Capital
$45.9B
CAGR 3-Years
1%
CAGR 5-Years
83%
CAGR 10-Years
41%
Merck & Co Inc
NYSE:MRK
Additional Paid In Capital
$44.5B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
1%
Zoetis Inc
NYSE:ZTS
Additional Paid In Capital
$1.2B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
2%
Eli Lilly and Co
NYSE:LLY
Additional Paid In Capital
$7.3B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
3%
No Stocks Found

Pfizer Inc
Glance View

Market Cap
145.4B USD
Industry
Pharmaceuticals

Pfizer Inc. is a global leader in the pharmaceutical industry, renowned for its commitment to innovative research and development that drives breakthroughs in healthcare. Founded in 1849, Pfizer has evolved into a powerhouse, particularly highlighted by its pivotal role in developing one of the first COVID-19 vaccines in collaboration with BioNTech. This achievement not only underscored the company's rapid response capabilities but also significantly boosted its revenue, showcasing its ability to pivot in times of global health crises. Investors are drawn to Pfizer not just for its historical legacy, but also for its diverse portfolio that includes treatments across various therapeutic areas such as oncology, immunology, and neurology, reflecting a balanced strategy poised for future growth. As Pfizer continues to navigate a post-pandemic world, its focus on innovation remains a cornerstone of its business strategy. With a robust pipeline of drugs in late-stage development and a strong commitment to mergers and acquisitions, Pfizer is determined to maintain market leadership while expanding its therapeutic offerings. Importantly, the company is also committed to shareholder value, consistently returning profits through dividends and share buybacks. For investors, Pfizer represents a compelling opportunity, merging stability with the potential for growth in an ever-evolving healthcare landscape, driven by advancements in science and technology.

PFE Intrinsic Value
24.05 USD
Overvaluation 6%
Intrinsic Value
Price

See Also

What is Pfizer Inc's Additional Paid In Capital?
Additional Paid In Capital
93.2B USD

Based on the financial report for Sep 29, 2024, Pfizer Inc's Additional Paid In Capital amounts to 93.2B USD.

What is Pfizer Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
2%

Over the last year, the Additional Paid In Capital growth was 1%. The average annual Additional Paid In Capital growth rates for Pfizer Inc have been 1% over the past three years , 1% over the past five years , and 2% over the past ten years .

Back to Top